NCX 4016

Drug Profile

NCX 4016

Alternative Names: NO-ASA; NO-aspirin

Latest Information Update: 19 Mar 2008

Price : $50

At a glance

  • Originator NicOx
  • Class Analgesics; Antiplatelets; Benzoic acids; Nonsteroidal anti-inflammatories; Small molecules; Vasodilators
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide donors; Nitric oxide stimulants; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Pain; Peripheral arterial occlusive disorders; Type 2 diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Mar 2008 Discontinued - Phase-II for Type-2 diabetes mellitus in Italy (PO)
  • 03 Mar 2008 Discontinued - Phase-II for Type-2 diabetes mellitus in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top